Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells

Journal of Immunology

Volumn 175, Issue 12, 2005, Pages 7819-7828

  Karimi, Mobin ^a   Cao, Thai M ^a   Baker, Jeanette A ^a   Verneris, Michael R ^b   Soares, Luis ^a,c   Negrin, Robert S ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Institute of Biomedical Pharmacology   (Brazil)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CELL SURFACE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN DAP10; RNA; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER IMMUNOTHERAPY; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONONUCLEAR CELL; MOUSE; MYELOMA CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PLASMACYTOMA; PRIORITY JOURNAL; RNA INTERFERENCE; SCID MOUSE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; WESTERN BLOTTING;

EID: 29144440145     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.12.7819     Document Type: Article

References (56)

1. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
2. Yokoyama, W. M., S. Kim, and A. R. French. 2004. The dynamic life of natural killer cells. Annu. Rev. Immunol. 22: 405-429.
3. Vely, F., and E. Vivier. 1997. Conservation of structural features reveals the existence of a large family of inhibitory cell surface receptors and noninhibitory/activatory counterparts. J. Immunol. 159: 2075-2077.
4. Wirthmueller, U., T. Kurosaki, M. S. Murakami, and J. V. Ravetch. 1992. Signal transduction by FcγRIII (CD16) is mediated through the γ chain. J. Exp. Med. 175: 1381-1390.
5. Lanier, L. L., B. C. Corliss, J. Wu, C. Leong, and J. H. Phillips. 1998. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391: 703-707.
6. Lanier, L. L., B. Corliss, J. Wu, and J. H. Phillips. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8: 693-701.
7. Vitale, M., C. Bottino, S. Sivori, L. Sanseverino, R. Castriconi, E. Marcenaro, R. Augugliaro, L. Moretta, and A. Moretta. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med 187: 2065-2072.
8. Cantoni, C., C. Bottino, M. Vitale, A. Pessino, R. Augugliaro, A. Malaspina, S. Parolini, L. Moretta, A. Moretta, and R. Biassoni. 1999. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189: 787-796.
9. Wu, J., H. Cherwinski, T. Spies, J. H. Phillips, and L. L. Lanier. 2000. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J. Exp. Med. 192: 1059-1068.
10. McVicar, D. W., L. S. Taylor, P. Gosselin, J. Willette-Brown, A. I. Mikhael, R. L. Geahlen, M. C. Nakamura, P. Linnemeyer, W. E. Seaman, S. K. Anderson, et al. 1998. DAP12-mediated signal transduction in natural killer cells: a dominant role for the Syk protein-tyrosine kinase. J. Biol. Chem. 273: 32934-32942.
11. Chang, C., J. Dietrich, A. G. Harpur, J. A. Lindquist, A. Haude, Y. W. Loke, A. King, M. Colonna, J. Trowsdale, and M. J. Wilson. 1999. Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties. J. Immunol. 163: 4651-4654.
12. Wu, J., Y. Song, A. B. Bakker, S. Bauer, T. Spies, L. L. Lanier, and J. H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
13. Billadeau, D. D., J. L. Upshaw, R. A. Schoon, C. J. Dick, and P. J. Leibson. 2003. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol. 4: 557-564.
14. Rosen, D. B., M. Araki, J, A, Hamerman, T. Chen, T. Yamamura, and L. L. Lanier. 2004. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173: 2470-2478.
15. Raulet, D. H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3: 781-790.
16. Bakker, A. B., E. Baker, G. R. Sutherland, J. H. Phillips, and L. L. Lanier. 1999. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc. Natl. Acad. Sci. USA 96: 9792-9796.
17. Aoki, N., S. Kimura, Y. Takiyama, Y. Atsuta, A. Abe, K. Sato, and M. Katagiri. 2000. The role of the DAP12 signal in mouse myeloid differentiation. J. Immunol. 165: 3790-3796.
18. Tomasello, E., P. O. Desmoulins, K. Chemin, S. Guia, H. Cremer, J. Ortaldo, P. Love, D. Kaiserlian, and E. Vivier. 2000. Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. Immunity 13: 355-364.
19. + T cells. J. Exp. Med. 197: 437-449.
20. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
21. Groh, V., R. Rhinehart, J. Randolph-Habecker, M. S. Topp, S. R. Riddell, and T. Spies. 2001. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2: 255-260.
22. Diefenbach, A., E. Tomasello, M. Lucas, A. M. Jamieson, J. K. Hsia, E. Vivier, and D. H. Raulet. 2002. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3: 1142-1149.
23. + T cells. Blood 103: 3065-3072.
24. Brooks, C. G., D. L. Urdal, and C. S. Henney. 1983. Lymphokine-driven "differentiation" of cytotoxic T-cell clones into cells with NK-like specificity: correlations with display of membrane macromolecules. Immunol. Rev. 72: 43-72.
25. Schmidt-Wolf, I. G., R. S. Negrin, H. P. Kiem, K. G. Blume, and I. L. Weissman. 1991. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 174: 139-149.
26. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153: 1687-1696.
27. + cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92: 3318-3327.
28. + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 7: 216-222.
29. + NK-T cells in the treatment of lymphoma. Biol. Blood Marrow Transplant. 7: 532-542.
30. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γproduction. Blood 97: 2923-2931.
31. Takayama, T., T. Sekine, M. Makuuchi, S. Yamasaki, T. Kosuge, J. Yamamoto, K. Shimada, M. Sakamoto, S. Hirohashi, Y. Ohashi, et al. 2000. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807.
32. Leemhuis, T., S. Wells, C. Scheffold, M. Edinger, and R. S. Negrin. 2005. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 11: 181-187.
33. Rubinson, D. A., C. P. Dillon, A. V. Kwiatkowski, C. Sievers, L. Yang, J. Kopinja, D. L. Rooney, M. M. Ihrig, M. T. McManus, F. B. Gertler, et al. 2003. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33: 401-406.
34. Wiznerowicz, M., and D. Trono. 2003. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77: 8957-8961.
35. Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
36. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15: 871-875.
37. Edinger, M., Y. A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin. 2003. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101: 640-648.
38. Brown, T. 2004. Analysis of RNA by Northern and slot-blot hybridization. In Current Protocols in Immunology, Vol. 3. J. E. Coligan, B. E. Bierer, D. H. Margulies, E. M. Shevach, and W. Strober, eds. Wiley & Sons, Hobokin, pp. 10.12.11-10.12.14.
39. Fuchtner, C., D. A. Emma, A. Manetta, G. Gamboa, R. Bernstein, and S. Y. Liao. 1993. Characterization of a human ovarian carcinoma cell line: UCI 101. Gynecol. Oncol. 48: 203-209.
40. Carbone, E., P. Neri, M. Mesuraca, M. T. Fulciniti, T. Otsuki, D. Pende, V. Groh, T. Spies, G. Pollio, D. Cosman, et al. 2005. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105: 251-258.
41. - antitumor T cells. Cancer Res. 64: 2175-2182.
42. Schmidt-Wolf, I. G., P. Lefterova, B. A. Mehta, L. P. Fernandez, D. Huhn, K. G. Blume, I. L. Weissman, and R. S. Negrin. 1993. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol. 21: 1673-1679.
43. + killer cells. Blood 86: 3493-3499.
44. O'Callaghan, C. A., A. Cerwenka, B. E. Willcox, L. L. Lanier, and P. J. Bjorkman. 2001. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 15: 201-211.
45. Vivier, E., J. A. Nunes, and F. Vely. 2004. Natural killer cell signaling pathways. Science 306: 1517-1519.
46. Garrity, D., M. E. Call, J. Feng, and K. W. Wucherpfennig. 2005. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc. Natl. Acad. Sci. USA 102: 7641-7646.
47. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. Kubin, D. Cosman, S. Ferrone, L. Moretta, et al. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62: 6178-6186.
48. Shum, B. P., L. R. Flodin, D. G. Muir, R. Rajalingam, S. I. Khakoo, S. Cleland, L. A. Guethlein, M. Uhrberg, and P. Parham. 2002. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J. Immunol. 168: 240-252.
49. Toyabe, S., U. Kaneko, and M. Uchiyama. 2004. Decreased DAP12 expression in natural killer lymphocytes from patients with systemic lupus erythematosus is associated with increased transcript mutations. J. Autoimmun. 23: 371-378.
50. Huppi, K., S. E. Martin, and N. J. Caplen. 2005. Defining and assaying RNAi in mammalian cells. Mol. Cell 17: 1-10.
51. Jamieson, A. M., A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle, and D. H. Raulet. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17: 19-29.
52. Diefenbach, A., A. M. Jamieson, S. D. Liu, N. Shastri, and D. H. Raulet. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1: 119-126.
53. Andre, P., R. Castriconi, M. Espeli, N. Anfossi, T. Juarez, S. Hue, H. Conway, F. Romagne, A. Dondero, M. Nanni, et al. 2004. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur. J. Immunol. 34: 961-971.
54. Paloneva, J., M. Kestila, J. Wu, A. Salminen, T. Bohling, V. Ruotsalainen, P. Hakola, A. B. Bakker, J. H. Phillips, P. Pekkarinen, et al. 2000. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet. 25: 357-361.
55. Norman, P. J., M. A. Cook, B. S. Carey, C. V. Carrington, D. H. Verity, K. Hameed, D. D. Ramdath, D. Chandanayingyong, M. Leppert, H. A. Stephens, et al. 2004. SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex. Immunogenetics 56: 225-237.
56. Stetson, D. B., M. Mohrs, R. L. Reinhardt, J. L. Baron, Z. E. Wang, L. Gapin, M. Kronenberg, and R. M. Locksley. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med. 198: 1069-1076.